Pemetrexed is a standard first-line treatment for advanced nonsquamous nonesmall-cell lung cancer (NSCLC), and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a standard first-line treatment for advanced nonsquamous NSCLC with activating EGFR mutations. Pemetrexed and EGFR TKIs have different mechanisms of action and minimally overlapping toxicity profiles; therefore, it is hypothesized that their combination might result in acceptable toxicity, provided that the synergistic antitumor activity observed in preclinical studies is achieved. This review summarizes clinical trials of pemetrexed in combination with an EGFR TKI for the treatment of advanced nonsquamous NSCLC in the first-and second-line settings, using intercalated, sequential, and concurrent treatment strategies. As would be expected, such strategies were most efficacious in patients with the activating EGFR mutations associated with response to an EGFR TKI. In the studies that compared a pemetrexed-EGFR TKI combination with pemetrexed alone or the EGFR TKI alone, the pemetrexed-EGFR TKI combination was more efficacious than the single-agent regimens. The pemetrexed-EGFR TKI combinations were generally associated with a higher incidence of grade 3/4 treatment-related adverse events than the single-agent regimens; however, such toxicities were clinically manageable. Future studies of pemetrexed-EGFR TKI combinations should focus on optimizing treatment strategies in patients with activating EGFR mutations.
Introduction
The development of better tolerated chemotherapeutic agents (eg, pemetrexed 1 ) and targeted agents (eg, epidermal growth factor receptor [EGFR] tyrosine kinase inhibitors [TKIs] 2 ) has expanded the treatment options for patients with advanced nonsquamous nonesmall-cell lung cancer (NSCLC).
are associated with improved response to EGFR TKIs in patients with advanced nonsquamous NSCLC and are most common in patients with the clinical characteristics of female gender, East Asian ethnicity, nonsmoking history, and adenocarcinoma histology. [15] [16] [17] [18] [19] TKIs are less toxic than traditional chemotherapy, with the most common toxicities being diarrhea, rash, mucositis, and paronychia. 20 EGFR TKIs are now standard first-line therapy for patients with advanced nonsquamous NSCLC with activating EGFR mutations and are not recommended for patients with wild-type EGFR.
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Rationale for Combining Pemetrexed and EGFR TKIs
Given their different mechanisms of action and minimally overlapping toxicity profiles, the combination of pemetrexed and an EGFR TKI might be expected to provide synergistic antitumor activity with manageable toxicity. This supposition is supported by preclinical studies, which have shown cytotoxic synergism between pemetrexed and erlotinib in several NSCLC cell lines. 23, 24 In addition, gefitinib has been shown to suppress TS expression in NSCLC cell lines 25 ; a lower level of TS expression appears to be associated with improved outcomes to pemetrexed treatment. 26 This narrative review summarizes the efficacy and safety results of studies that have assessed pemetrexed in combination with an EGFR TKI in the treatment of patients with advanced nonsquamous NSCLC, using intercalated, sequential, and concurrent treatment strategies. Although this review covers many of the key trials assessing pemetrexed in combination with an EGFR TKI, it is not intended to be a comprehensive systematic review of the topic.
Initial Studies of First-line Chemotherapy Plus EGFR TKI Treatment
The initial evaluation of chemotherapy plus an EGFR TKI included 4 large, double-blind, randomized, phase 3 studies (TRIBUTE, 27 TALENT, 28 INTACT 1, 29 INTACT 2 30 ) of firstline (nonepemetrexed-containing) platinum doublet chemotherapy with concurrent erlotinib or gefitinib. These studies showed no clinical benefit over chemotherapy alone in patients with advanced NSCLC. Two hypotheses have been proposed for this lack of effect. First, these studies began before the relationship between activating EGFR mutations and response to EGFR TKIs was identified. 31 Hence, patients with wild-type EGFR, who are not likely to respond to EGFR TKI treatment, were enrolled in these studies. 31, 32 Second, based on preclinical and clinical studies, it has been proposed that there may be antagonism between the EGFR TKI and platinum-based chemotherapy when given concurrently. 33, 34 In patients with wild-type EGFR, EGFR TKI treatment results in cell cycle arrest and accumulation of cells in the G1 phase, which might render the tumor cells less sensitive to cytotoxic drugs that act during the S and G2/M phases. 33, 35 In contrast, in patients with EGFR mutations, EGFR TKI treatment causes increased apoptosis. 33, 35 In support of the hypothesis that patient selection affected the outcomes of these early phase 3 studies of chemotherapy plus an EGFR TKI, subgroup analyses showed improvements in progression-free survival (PFS) and/or OS for the chemotherapy plus EGFR TKI combination over chemotherapy alone in patients who had never smoked 27, 28 or who had tumors with adenocarcinoma histology 30 (ie, in patients with clinical characteristics associated with activating EGFR mutations).
To address the hypothesis that the relative timing of the chemotherapy and EGFR TKI might influence the clinical outcomes, alternative strategies for combining pemetrexed with an EGFR TKI have been investigated. 
Intercalated Combination of Pemetrexed and EGFR TKI Treatment
Rationale for Intercalated Treatment Strategies
Preclinical studies have shown that the sequence of administration of pemetrexed and erlotinib affects the cytotoxicity of the combination. Cytotoxic synergism in NSCLC cell lines was observed when pemetrexed and erlotinib were administered concurrently or when pemetrexed was followed by erlotinib administration, but not when erlotinib was followed by pemetrexed administration. 24 The antagonism observed when erlotinib was administered before pemetrexed was the result of erlotinib causing G1 phase arrest, which protected the tumor cells from the cytotoxic effects of the subsequently administered pemetrexed. 24 This effect might have contributed to the lack of efficacy observed in the early studies of chemotherapy and concurrent EGFR TKI treatment, [27] [28] [29] [30] which used a schedule of continuous administration of the EGFR TKI. In these studies, apart from the first day of treatment, the chemotherapy was effectively administered after the EGFR TKI, potentially allowing EGFR TKIeinduced G1 phase arrest to block the cytotoxic effects of the subsequent chemotherapy doses (depending on EGFR mutation status). This situation might be overcome by intercalated treatment strategies that use intermittent dosing of the chemotherapy and EGFR TKI to achieve pharmacodynamic separation of the therapies. 33 
Intercalated Combination of Second-line Pemetrexed Plus EGFR TKI Treatment
Two phase 1 studies conducted in previously treated patients with advanced NSCLC who were unselected with respect to EGFR mutations (or clinical characteristics associated with EGFR mutations) showed promising efficacy and favorable tolerability with intercalated treatment strategies that used pemetrexed as the chemotherapy component. 36, 37 To further evaluate this treatment strategy using
pemetrexed, an open-label, randomized, phase 2 study was conducted that compared pemetrexed and erlotinib in an intercalated regimen with pemetrexed alone and erlotinib alone in a clinically selected population of never-smokers with advanced nonsquamous NSCLC (Study S103). 38 Patients were randomized to second-line treatment with pemetrexed (500 mg/m 2 on day 1 of a 21-day cycle) plus erlotinib (150 mg/d on days 2-14; n ¼ 78), erlotinib (150 mg/d; n ¼ 80), or pemetrexed (500 mg/m 2 on day 1 of a 21-day cycle; n ¼ 82). Patients receiving pemetrexed in this study (and in the other studies described in this review) also received dexamethasone, folic acid, and vitamin B 12 supplementation as per the pemetrexed prescribing information. With this intercalated regimen, there was an interval of 7 days between the end of erlotinib administration and the next administration of pemetrexed. An interval of 6 days without erlotinib has been found to be sufficient to allow cells to reenter the cell cycle from G1 phase arrest and restore their sensitivity to chemotherapy. 39 In this phase 2 study, there was a statistically significant difference in PFS across the 3 treatment arms (global P ¼ .003), with pemetrexed-erlotinib significantly better than both erlotinib alone (hazard ratio [HR] 0.57; 95% confidence interval [CI], 0.40-0.81; P ¼ .002) and pemetrexed alone (HR 0.58; 95% CI, 0.39-0.85, P ¼ .005). 38 Median PFS was 7.4 months in the pemetrexed-erlotinib arm, 3.8 months in the erlotinib-alone arm, and 4.4 months in the pemetrexed alone arm. There was no significant difference between erlotinib alone and pemetrexed alone (HR 0.99; 95% CI, 0.70-1.40; P ¼ .959). There were no statistically significant differences in OS across the 3 treatment arms, although it should be noted that the study was not powered for OS and the high censor rate (45.8%) might have limited the analysis. 38 In addition, the extent of third-line or further treatment, including cross-over of pemetrexed and EGFR TKIs, may have contributed to the lack of difference in OS among the 3 treatment arms.
A subgroup analysis of this study was conducted to assess the effect of EGFR mutation status on PFS. 38 In patients with EGFR mutations (n ¼ 24), there appeared to be a PFS advantage with pemetrexed-erlotinib over pemetrexed alone but not erlotinib alone.
In patients with wild-type EGFR (n ¼ 19), there appeared to be a PFS advantage with pemetrexed-erlotinib over both erlotinib alone and pemetrexed alone. However, it should be noted that EGFR mutation status could be determined for only 43 (18%) of the 240 patients in the study. As East Asian ethnicity is associated with an increased likelihood of having the activating EGFR mutations associated with response to an EGFR TKI, a subgroup analysis was conducted to assess the outcomes in the East Asian patients enrolled in the study (who constituted approximately 55% of the study population). 40 The PFS results for the East Asian subpopulation were consistent with those for the overall study population, with a statistically significant difference in PFS across the 3 arms (global P ¼ .003), with pemetrexed-erlotinib significantly better than both erlotinib alone (HR 0.48; 95% CI, 0.29-0.79; P ¼ .004) and pemetrexed alone (HR 0.40; 95% CI, 0.23-0.70; P ¼ .001). Median PFS in the East Asian subpopulation was 7.4 months in the pemetrexed-erlotinib arm, 4.5 months in the erlotinib-alone arm, and 4.0 months in the pemetrexed-alone arm. Safety analyses in this study showed that the incidence of grade 3/ 4 treatment-related adverse events (AEs) was higher for pemetrexederlotinib (60.0%) than erlotinib alone (12.0%) or pemetrexed alone (28.9%), as expected for treatment with a 2-drug combination compared with a single agent. 38 However, there were no unexpected toxicities, most of the reported events were consistent with toxicity profiles of the individual agents, and the toxicities were generally clinically manageable. The combined efficacy and safety results from this study indicated that second-line treatment with an intercalated pemetrexed-erlotinib regimen was associated with improved PFS compared with either agent alone, with clinically manageable toxicity, in this clinically selected population of patients with advanced nonsquamous NSCLC.
Intercalated Combination of First-line Pemetrexed Plus EGFR TKI Treatment
An intercalated pemetrexed-erlotinib regimen has also been evaluated in the first-line setting in an exclusively EGFR mutationepositive study population. 41 In this single-arm, phase 2 study, 26 patients with advanced nonsquamous NSCLC and confirmed activating EGFR mutations received first-line treatment with pemetrexed (500 mg/m 2 on day 1 of a 21-day cycle) plus gefitinib (250 mg/d on days 2-16). This intercalated regimen allowed an interval of 5 days between the end of administration of the EGFR TKI and the next administration of pemetrexed. The overall response rate and disease control rate were high, at 84.6% and 96.2%, respectively, accompanied by a median PFS of 18.0 months and acceptable toxicity. 41 The results from this single-arm study 41 were supported by a randomized study that compared an intercalated regimen of pemetrexed plus gefitinib with pemetrexed alone in patients with advanced NSCLC with EGFR mutations. 42 In the randomized study, patients received first-line treatment with pemetrexed (500 mg/m 2 on day 1 of a 21-day cycle) plus gefitinib (250 mg/d on days 2-16; n ¼ 45) or with pemetrexed (500 mg/m 2 on day 1 of a 21-day cycle) plus placebo (n ¼ 45). Median PFS was significantly longer with pemetrexed plus gefitinib than pemetrexed alone (18 vs. 14 months, P < .05). Median OS was similar between the 2 arms (34 vs. 32 months, P > .05); the use of postdiscontinuation therapy was not reported. The difference in AEs between the 2 treatment groups was not statistically significant, indicating acceptable toxicity for the pemetrexed plus gefitinib combination.
Sequential Combination of Pemetrexed and EGFR TKI Treatment
Sequential Combination of First-line Pemetrexed Plus EGFR TKI Treatment: Phase 2 Evaluation
Another approach for combining chemotherapy with an EGFR TKI is a sequential treatment strategy, in which induction chemotherapy is followed by a maintenance phase with the EGFR TKI. This treatment strategy has been investigated with pemetrexed as a component of the chemotherapy in an open-label, randomized, phase 2 study in which pemetrexed-cisplatin chemotherapy was followed by a maintenance phase with either gefitinib or pemetrexed as first-line treatment in a clinically selected population of East Asian, neversmoker patients with advanced NSCLC of various histological type. 43 In this study (Study S110), patients were randomized to Safety analyses in this study showed that grade 3/4/5 toxicity was low and similar between the 2 treatment arms, indicating that either gefitinib or pemetrexed could be used as maintenance treatment after induction chemotherapy without increased toxicity. 43 The small number of samples available for EGFR testing prevented analysis of outcomes by EGFR mutation status 43 and, therefore, determination of whether patients with EGFR mutations would derive benefit from a sequential treatment strategy as well as from concurrent and intercalated treatment strategies for combining pemetrexed with an EGFR TKI. Nevertheless, this study showed that pemetrexedcontaining induction chemotherapy followed by maintenance gefitinib resulted in improved PFS compared with maintenance pemetrexed in a clinically selected population of patients with advanced NSCLC and informed the design of the randomized, phase 3 S131 study.
Sequential Combination of First-line Pemetrexed Plus EGFR TKI Treatment: Phase 3 Evaluation
Another sequential treatment strategy was assessed in an open-label, randomized, phase 3 study, in which pemetrexed-cisplatin chemotherapy followed by a maintenance phase with gefitinib was compared with gefitinib monotherapy as first-line treatment in patients with advanced nonsquamous NSCLC clinically selected to respond to gefitinib (East Asian light ex-smokers/never-smokers with adenocarcinoma). 44 In this study (Study S131), patients were randomized to 6 cycles of pemetrexed (500 mg/m 2 on day 1 of a 21-day cycle) and cisplatin (75 mg/m 2 on day 1) followed by gefitinib (250 mg/d; PC/ gefitinib arm; n ¼ 118) or gefitinib monotherapy (250 mg/d; gefitinib monotherapy arm; n ¼ 118). In both treatment arms, gefitinib was administered until disease progression, study discontinuation, or death. Median PFS was not significantly different between the PC/gefitinib and gefitinib monotherapy arms in the intention-to-treat (ITT) population, although the HR for PFS favored PC/gefitinib (8.38 vs. 9.63 months; unadjusted HR 0.85; 95% CI, 0.63-1.13; P ¼ .261). Analysis by EGFR mutation status showed that the HR for PFS also favored PC/gefitinib in patients with EGFR mutations (n ¼ 50; adjusted HR 0.83; 95% CI, 0.42-1.62; P ¼ .585) and in patients with wild-type EGFR (n ¼ 24; adjusted HR 0.18; 95% CI, 0.06-0.51; P ¼ .001); this benefit was more substantial and reached statistical significance in patients with wild-type EGFR. The authors stated that in patients in the ITT population and patients with EGFR mutations, the HRs were not constant and, therefore, should be interpreted with caution. In addition, the small number of patients for whom EGFR mutation status could be determined (n ¼ 74) should be kept in mind when interpreting these results. However, despite the small number of patients with wild-type EGFR, the significantly shorter median PFS with gefitinib monotherapy compared with PC/gefitinib (1.35 vs. 9.92 months) provided further evidence that patients with wild-type EGFR do not benefit from treatment with an EGFR TKI. In addition, quality of life analyses of this study showed poorer outcomes in patients with wild-type EGFR treated with gefitinib monotherapy than in those treated with PC/gefitinib. 45 The final OS results from this study found that median OS was similar between the 2 treatment arms. 46 Median OS was 26.9 months in the PC/gefitinib arm and 27.9 months in the gefitinib monotherapy arm (unadjusted HR 0.94; 95% CI, 0.68-1.31; P ¼ .717). When analyzed by EGFR mutation status, median OS was longer with PC/gefitinib than with gefitinib monotherapy in patients with wild-type EGFR (28.4 vs. 8.9 months) and longer with gefitinib monotherapy than with PC/gefitinib in patients with EGFR mutations (45.7 vs. 32.4 months). Again, the small number of patients for whom EGFR mutation status could be determined should be kept in mind when interpreting these results. Safety analyses in this study showed that, for the entire treatment period, the incidence of grade 3/4 treatment-related AEs was higher for PC/gefitinib (34%) than for gefitinib monotherapy (16%), which is expected for a treatment regimen composed of 3 drugs compared with a single agent. 44 This study found no difference in PFS for PC/gefitinib versus gefitinib monotherapy for the ITT population in this clinically selected population; however, the overall study results indicated that pemetrexed plus cisplatin is an active treatment regimen that can be combined with gefitinib maintenance therapy without additional safety concerns in East Asian never-smoker patients with advanced nonsquamous NSCLC, regardless of EGFR mutational status.
Although Study S110 and Study S131 provide useful efficacy and safety information on sequential regimens, the full potential benefit of the sequential treatment strategy for combining pemetrexed with an EGFR TKI with respect to efficacy is yet to be determined. With the current recommendation that EGFR TKIs should be used only in patients with activating EGFR mutations, 12 further investigation of this treatment strategy should be conducted in an exclusively EGFR mutationepositive study population. The importance of EGFR mutation status in response to EGFR TKI treatment is highlighted in the summary of randomized studies assessing pemetrexed in combination with an EGFR TKI in Table 2 .
Response rates and median PFS values were much higher in exclusively EGFR mutationepositive study populations 41, 42, 47 (not including the single-arm study conducted in patients who had progressed on gefitinib/erlotinib 48 ) than in clinically selected study populations, 38, 43, 44 even though these populations were "enriched"
for the presence of clinical characteristics associated with an increased likelihood of response to an EGFR TKI.
Concurrent Combination of Pemetrexed and EGFR TKI Treatment
Concurrent Combination of First-line Pemetrexed and EGFR TKI Treatment in EGFR Mutationepositive Patients
It is possible that the potential benefit of adding an EGFR TKI to chemotherapy may have been obscured by the inclusion of patients with wild-type EGFR in the early studies that used concurrent strategies for combining chemotherapy with an EGFR TKI. [27] [28] [29] [30] To address this possibility, the efficacy and safety of pemetrexed with concurrent gefitinib was assessed in a recent study that enrolled only EGFR mutationepositive patients (Study JMIT). 47 In this open-label, randomized, phase 2 study, East Asian patients with advanced nonsquamous NSCLC and confirmed activating EGFR mutations were randomized to first-line treatment with pemetrexed (500 mg/m 2 on day 1 of a 21-day cycle) plus gefitinib (250 mg/d; n ¼ 126) or gefitinib (250 mg/d; n ¼ 65) alone. Median PFS was significantly longer with pemetrexed plus gefitinib than gefitinib alone (15.8 vs. 10.9 months; adjusted HR 0.68; 95% CI, 0.48-0.96; P ¼ .029). This demonstrates that the combination of pemetrexed with an EGFR TKI improves efficacy compared with the EGFR TKI alone in patients with advanced nonsquamous NCSLC with activating EGFR mutations. As observed for the overall study population, there were improvements in PFS for pemetrexed plus gefitinib compared with gefitinib alone in the subgroups of patients with exon 19 deletions or the L858R point mutation, the most common EGFR mutations. 47 In addition, the duration of response was prolonged in the overall study population with pemetrexed plus gefitinib compared with gefitinib alone (15.4 vs. 11.3 months), which reflects and partly explains the relative prolongation in PFS. 47 It is possible that the addition of pemetrexed to gefitinib may delay the development of EGFR TKI resistance that ultimately occurs in most patients receiving treatment with an EGFR TKI. 49 The incidence of grade 3/4 treatment-related AEs was significantly higher (P ¼ .001) for gefitinib plus pemetrexed (42%) than for gefitinib alone (19%), reflecting the additional events expected for a 2-drug combination compared with monotherapy. However, the toxicities for the pemetrexed plus gefitinib combination were manageable, as evidenced by the high relative dose intensity of pemetrexed (93%) and gefitinib (96%) in the combination arm (the relative dose intensity of gefitinib in the gefitinib alone arm was 98%). Although the early studies of chemotherapy with concurrent EGFR TKI treatment were not promising, this study shows that the treatment strategy of combining pemetrexed with concurrent EGFR TKI treatment is beneficial in the population of patients most likely to respond to an EGFR TKI (ie, patients with activating EGFR mutations).
Concurrent Combination of First-line Pemetrexed Plus Carboplatin and EGFR TKI Treatment in EGFR Mutationepositive Patients
A concurrent treatment strategy in which pemetrexed was combined with carboplatin and gefitinib has also been investigated in a phase 2 study (NEJ005). 50 In this study, patients with advanced nonsquamous NSCLC were randomized to first-line treatment with a concurrent regimen (pemetrexed 500 mg/m 2 and carboplatin 6 Â area under the curve on day 1 of a 21-day cycle and concurrent gefitinib 250 mg/d for up to 6 cycles, followed by concurrent pemetrexed and gefitinib maintenance; n ¼ 41) or a sequential alternating regimen (8 weeks of gefitinib and then 2 cycles of pemetrexed-carboplatin, repeated 3 times, followed by alternating gefitinib and pemetrexed maintenance; n ¼ 39 The authors stated that the reasons for the improved survival with the concurrent regimen were not readily identifiable, but suggested that the concurrent strategy might prevent the development of EGFR TKI resistance. Almost half of the patients in the study reported a hematological AE of grade 3 or higher; however, these events were predictable and manageable. The concurrent regimen is currently being evaluated against gefitinib alone in a randomized phase 3 study (NEJ009). 51 
Concurrent Combination of Second-line Pemetrexed and EGFR TKI Treatment
The efficacy and safety of second-line treatment with pemetrexed and concurrent erlotinib was assessed in patients who had failed one prior platinum-based chemotherapy regimen (Study S102). 52 In this open-label, randomized, phase 2 study, patients 
Conclusions
The potential benefits of combining chemotherapy with an EGFR TKI for the treatment of advanced NSCLC were initially obscured by the studies being conducted in unselected patient populations. With the identification of the relationship between activating EGFR mutations and response to EGFR TKIs, treatment strategies involving pemetrexed in combination with an EGFR TKI could be evaluated in the patient populations likely to respond to both pemetrexed and an EGFR TKI (ie, patients with clinical characteristics associated with response to an EGFR TKI and, more specifically, patients with advanced nonsquamous NSCLC with activating EGFR mutations). In addition, the relative timing of pemetrexed and EGFR TKI administration should be considered, as confirmed by a recently published preclinical study that showed that gefitinib plus pemetrexed administered first with intercalated gefitinib and pemetrexed administered first with intercalated gefitinib (but not gefitinib administered first with intercalated pemetrexed) resulted in tumor regression and prevented the development of gefitinib resistance. 53 Based on these preclinical results, it was suggested that continuous administration of gefitinib in combination with pemetrexed at the start of treatment and then at regular intervals (ie, a concurrent regimen) is a potential treatment strategy for clinical evaluation. 53 A recent phase 2 study found first-line pemetrexed chemotherapy plus concurrent EGFR TKI to be a potential treatment option for patients with advanced nonsquamous NSCLC with activating EGFR mutations, 47 but this finding should be validated in a large-scale, randomized, phase 3 study. Intercalated and sequential treatment strategies also warrant further consideration in the appropriate patient population.
